BARRY FENTON: Open Payments
NPI 1417082892 · DALLAS, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,079 in 56 payments from 16 companies in 2025. Trend: 2023 $1,396 · 2024 $1,049 · 2025 $1,079
Food & beverage: $1,079
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 21 | $205 |
| Axsome Therapeutics, Inc. | 6 | $191 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 6 | $135 |
| Vanda Pharmaceuticals Inc. | 3 | $96 |
| Alkermes, Inc. | 2 | $60 |
| Corium, LLC | 2 | $59 |
| E.R. Squibb & Sons, L.L.C. | 3 | $57 |
| Neos Therapeutics, LP | 3 | $50 |
| Tris Pharma Inc | 2 | $49 |
| Lundbeck LLC | 2 | $43 |
Products named: VRAYLAR, Auvelity, CAPLYTA, FANAPT, REXULTI, Azstarys, COBENFY, Adzenys XR-ODT.
Industry payments across TX — which companies pay providers there.
